A promising direction for the creation of new biologically active derivatives of the alkaloid lupinine is the synthesis of “hybrid molecules” that combine a fragment of the alkaloid and the pharmacophore of 1,2,3-triazole in their structure. From a biological perspective, this work presents the first X-ray diffraction study of a single crystal of (1S,9aR)-1-({4-[4-(Benzyloxy)-3-methoxyphenyl]-1H-1,2,3-triazol-1-yl}methyl)octahydro-2H-quinolizine, a new, recently synthesized 1,2,3-triazole derivative of lupinine. A comparison of theoretically predicted and experimentally observed structural parameters was carried out. The FTIR spectroscopy study and vibrational properties calculations allowed us to interpret the FTIR absorption spectrum and localize specific vibrational modes in quinolizidine, 1,2,3-triazole, and benzene rings. Such information can be fruitful for further characterization of the synthesis process and products. The molecular docking of the compound was performed. It was shown that the studied molecules are capable of interacting with the Mpro binding site via non-covalent and hydrophobic interactions with subsites S3 (Met165, Glu166, Leu167, Pro168) and S5 (Gln189, Thr190, Gln192), which ensure the stabilization of the Mpro substrate. Blocking of the active site of the enzyme in the region of the oxyanion hole does not occur, but stable stacking interactions with the π-system of one of the catalytic amino acids, His41, are observed.
This study investigates the phytochemical composition and acetylcholinesterase (AChE) inhibitory activity of Anabasis salsa (C.A. Mey.) Benth. ex Volkens (Chenopodiaceae), with a particular focus on secondary metabolites present in its extracts. The plant extracts were profiled using HPLC-ESI-QTOF-MS/MS, revealing a diverse composition including organic acids, phenolic compounds, flavonoids, and alkaloids. The latter were represented by anabasine and lupinine that were identified as significantly present compounds. Depending on the type of extract and plant part, lupinine was present in the extracts at a quantity range from 0.0033 to 6.35%, and its highest concentration was noted in the acidified macerate from the overground parts of the plant. Centrifugal partition chromatography (CPC) operated using the solvent system composed of MTBE:ACN:n-BuOH:H2O, 2:2:1:5 (v/v/v/v), was applied for the fractionation of the most promising extract, enabling efficient separation using a biphasic solvent system. The obtained fractions were evaluated for AChE inhibitory activity, and the most active fractions were found to contain lupinine, which was successfully isolated in a purified fraction using CPC. These findings highlight lupinine as a significant bioactive compound with neuroprotective potential and demonstrate the applicability of CPC as an efficient and scalable method for the isolation of alkaloids from complex plant matrices.
В исследовании изучены технологические параметры и химический состав надземной части Linaria vulgaris Mill., собранной во время цветения в Карагандинской области (Республика Казахстан). Сырьё отличалось оптимальной удельной, и насыпной массой, пористостью и коэффициентом поглощения экстрагента. Проведена экстракция методом мацерации с использованием 96%-ного этанола с последующим упариванием на ротационном испарителе. В результате получен экстракт с выходом 9,19 ± 0,16%. В ходе фитохимического исследования методом HPLC-ESI-QTOF-MS/MS выявлен широкий спектр соединений, включая флавоноиды, фенольные кислоты и фитостерины. Сравнение экспериментальных и теоретических значений m/z подтвердило точность идентификации соединений. Полученные результаты демонстрируют потенциал Linaria vulgaris Mill. как источника биологически активных веществ и подтверждают эффективность предложенного метода для стандартизации и последующих фармакологических исследований.
The antiviral activity of compound (5) was demonstrated by a reduction in influenza A viral infectivity of 2.0 log10 for H3N2 (99% inactivation) and 1.9 log10 for H1N1 (98.7% inactivation) at a dose of 0.4 mg/embryo. The compound demonstrated no noticeable embryotoxicity at the maximum tested dose of 0.4 mg/embryo, while the LD50 was not reached within the investigated concentration range. Notably, its therapeutic index outperforms rimantadine and oseltamivir. Furthermore, a scalable 8-stage laboratory production protocol was successfully validated. These findings position compound (5) as a highly promising, low-toxicity domestic prototype for the development of innovative, multi-targeted anti-influenza pharmaceutical drugs.